FDA approval to expand the use of HYQVIA to treat primary immunodeficiency in children – Takeda
Takeda announced that the FDA has approved a supplemental biologics license application (sBLA) to expand the use of HYQVIA to treat primary immunodeficiency (PI) in children 2-16 years… read more.